langue originale | Anglais |
---|---|
Pages (de - à) | 245-248 |
Nombre de pages | 4 |
journal | European Journal of Cancer |
Volume | 151 |
Les DOIs | |
état | Publié - 1 juil. 2021 |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: European Journal of Cancer, Vol 151, 01.07.2021, p. 245-248.
Résultats de recherche: Contribution à un journal › Editorial
TY - JOUR
T1 - CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer
AU - Rouanne, Mathieu
AU - Arpaia, Nicholas
AU - Marabelle, Aurélien
N1 - Funding Information: Mathieu Rouanne has received pre-clinical and clinical research grants (institutional funding) from AstraZeneca and Ipsen . Nicholas Arpaia discloses a financial interest in GenCirq, Inc. Aurélien Marabelle has received research grants from Astrazeneca , BMS , Boehringer Ingelheim , Janssen Cilag , Merck , Novartis , Pfizer , Roche , Sanofi ; has received Pre-Clinical and Clinical Research Grants (Institutional Funding) from Merus , BMS , Boehringer Ingelheim , Transgene , Fondation MSD Avenir , Sanofi ; is a member of Clinical Trial Steering Committee: NCT02528357 (GSK), NCT03334617 (AZ) and Data Safety and Monitoring Board: NCT02423863 (Sponsor: Oncovir), NCT03818685 (Sponsor: Centre Léon Bérard); has participated in Scientific Advisory Boards: Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, Tesaro/GSK, Oncosec, Pfizer, Seattle Genetics, Astra Zeneca/Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, Pierre Fabre, RedX pharma, OSE Immunotherapeutics, Medicxi, HiFiBio, IMCheck, MSD; has received teaching/speaker activities from Roche/Genentech, BMS, Merck (MSD), Merck Serono, Astra Zeneca/Medimmune, Amgen, Sanofi, Servier; has received fees for Scientific & Medical Consulting: Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, Imaxio, Sanofi/BioNTech, Molecular Partners, Pillar Partners, BPI, Faron; has received non-financial support (travel expenses) from Astra Zeneca, BMS, Merck (MSD), Roche; is co-founder and shareholder of Pegascy SAS & PEGA-1 SAS; is patent holder: patent issued (not licensed): “Humanised and Chimeric Monoclonal Antibodies to CD81”, Stanford Office of Technology Licensing, 3000 El Camino Real, Bldg. 5, Suite 300, Palo Alto, CA 94306-2100. U.S. Application Serial No. 62/351,054. Funding Information: Mathieu Rouanne has received pre-clinical and clinical research grants (institutional funding) from AstraZeneca and Ipsen. Nicholas Arpaia discloses a financial interest in GenCirq, Inc. Aur?lien Marabelle has received research grants from Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; has received Pre-Clinical and Clinical Research Grants (Institutional Funding) from Merus, BMS, Boehringer Ingelheim, Transgene, Fondation MSD Avenir, Sanofi; is a member of Clinical Trial Steering Committee: NCT02528357 (GSK), NCT03334617 (AZ) and Data Safety and Monitoring Board: NCT02423863 (Sponsor: Oncovir), NCT03818685 (Sponsor: Centre Le?on Be?rard); has participated in Scientific Advisory Boards: Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, Tesaro/GSK, Oncosec, Pfizer, Seattle Genetics, Astra Zeneca/Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, Pierre Fabre, RedX pharma, OSE Immunotherapeutics, Medicxi, HiFiBio, IMCheck, MSD; has received teaching/speaker activities from Roche/Genentech, BMS, Merck (MSD), Merck Serono, Astra Zeneca/Medimmune, Amgen, Sanofi, Servier; has received fees for Scientific & Medical Consulting: Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, Imaxio, Sanofi/BioNTech, Molecular Partners, Pillar Partners, BPI, Faron; has received non-financial support (travel expenses) from Astra Zeneca, BMS, Merck (MSD), Roche; is co-founder and shareholder of Pegascy SAS & PEGA-1 SAS; is patent holder: patent issued (not licensed): ?Humanised and Chimeric Monoclonal Antibodies to CD81?, Stanford Office of Technology Licensing, 3000 El Camino Real, Bldg. 5, Suite 300, Palo Alto, CA 94306-2100. U.S. Application Serial No. 62/351,054.
PY - 2021/7/1
Y1 - 2021/7/1
KW - Anti–PD-L1
KW - Bladder cancer
KW - CXCL13
KW - Tertiary lymphoid structures
UR - http://www.scopus.com/inward/record.url?scp=85106322935&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2021.03.054
DO - 10.1016/j.ejca.2021.03.054
M3 - Editorial
C2 - 33972155
AN - SCOPUS:85106322935
SN - 0959-8049
VL - 151
SP - 245
EP - 248
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -